EP
ORKA icon

Essential Partners’s Oruka Therapeutics ORKA Stock Holding History

Essential Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$916 Hold
11
– – ﹤0.01% 2217
2026
Q2 		$1.05K Sell
11
-16
-59% -$1.07K ﹤0.01% 2231
2026
Q1 		$1.32K Hold
27
– – ﹤0.01% 2149
2025
Q4 		$818 Hold
27
– – ﹤0.01% 2093
2025
Q3 		$519 Buy
+27
New +$400 ﹤0.01% 2197

Other funds holding ORKA

Secure Asset Management
Secure Asset Management Troy, Michigan $753M AUM 20.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Mather Group
Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's ORKA Position: Q3 2026 in Review

Essential Partners held its Oruka Therapeutics (ORKA) position steady in Q3 2026 at 11 shares worth $916. The position accounts for ﹤0.01% of the portfolio, ranked #2217.

Essential Partners first reported a position in ORKA in Q3 2025 and has held it in 5 quarters since. The position peaked at $1.32K in Q1 2026. 10 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • Essential Partners held 11 shares of Oruka Therapeutics worth $916 as of Q3 2026.
  • Essential Partners left its Oruka Therapeutics share count unchanged in Q3 2026.
  • Oruka Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2217 holding.
  • Essential Partners first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Essential Partners's Oruka Therapeutics position peaked at $1.32K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.